cryocompression therapy for peripheral neuropathy in patients with multiple myeloma

Conditions: Chemotherapy-induced Peripheral Neuropathy; Plasma Cell Myeloma

Summary: this trial studies how well cryocompression therapy works in reducing bortezomib-induced peripheral neuropathy in patients with multiple myeloma. peripheral neuropathy (nerve pain or tingling in hands or feet) is a common side effect of chemotherapy such as bortezomib that affects the quality of life and amount of chemotherapy that can be given to many cancer patients. cryocompression is a treatment where a glove and a boot are worn to cool down the skin. this cooling treatment is safe and does not interfere with chemotherapy treatment. daily cryocompression therapy may reduce neuropathy caused by bortezomib chemotherapy.

primary objectives: i. to assess the feasibility of daily cryocompression therapy in multiple myeloma patients with bortezomib-induced peripheral neuropathy (bipn). secondary objectives: i. to examine the change in patient-reported assessment of neuropathy based on the sensory, motor and autonomic neuropathy scores on the european organization for research and treatment of cancer (eortc) quality of life questionnaire (qlq)-cancer-induced peripheral neuropathy (cipn20) (patient-reported outcome \[pro\]) from baseline to 4 and 8 weeks after the start of cryocompression therapy. ii. to examine the change in physician graded assessment of peripheral neuropathy by national cancer institute (nci) common terminology criteria for adverse events (ctcae) version (v) 5.0 criteria from baseline to 4 and 8 weeks after the start of cryocompression therapy. iii. to assess the effect on sensory and motor nerve function via nerve conduction study (ncs) (e.g. conduction velocity, latency, and amplitude) and neuro-ultrasound after 8 weeks of daily cryocompression therapy. exploratory objectives: i. to explore the effect of 8 weeks of cryocompression on changes in digital artery perfusion as measured by ultrasound (us). ii. to examine the associations among the peripheral nerve assessment measures (nerve conduction and peripheral nerve us) with the patient reported outcomes (eortc qlq-cipn20, pro-ctcae) at baseline, week 4, week 8, and for the change from baseline to week 8. outline: patients undergo home cryocompression therapy treatments on their non-dominant hand and foot over 30 minutes daily for 8 weeks. after completion of cryocompression therapy, patients are followed up at 30 days.

Eligibility criteria:
inclusion criteria: * patients must have histologically or cytologically confirmed multiple myeloma (any international staging system \[iss\] stage). * clinical symptoms of bortezomib-induced peripheral neuropathy as measured by the nci-ctcae. cohort 1: patients with clinically documented ctcae grade greater than or equal 2 neuropathy. cohort 2: patients with clinically documented ctcae grade 1-2 neuropathy. • currently or previously received bortezomib-containing regimen cohort 1: patients who have previously received a bortezomib-containing regimen and have clinically documented neuropathy that is attributed to the bortezomib containing regimen. cohort 2: patients who are currently receiving a bortezomib-containing regimen and have clinically documented neuropathy that is attributed to the bortezomib containing regimen. * age must be greater than or equal to 18 years. * eastern cooperative oncology group (ecog) =\< 4. * life expectancy \>= 6 months. * ability to understand and the willingness to sign an institutional review board (irb)-approved informed consent document. exclusion criteria: * self-reported or documented history of pre-existing peripheral neuropathy prior to initiation of bortezomib therapy. * other explanatory etiology for neuropathy. * presumptive evidence of congestive heart failure. * current deep vein thrombosis or pulmonary embolism (diagnosed within the past 6 months). * current pulmonary edema. * unable to provide accurate medical history. * pregnant women are excluded from this study because they will not be receiving myeloma standard of care (soc) therapy or bortezomib-based therapy per inclusion criteria. * current or previously documented inflammatory phlebitis; thrombophlebitis; decompensated cardiac insufficiency; arterial dysregulation; erysipelas; carcinoma or carcinoma metastasis in the affected extremity; decompensated hypotonia; venous or arterial occlusive disease; or raynaud's disease; * current monoclonal gammopathy of undetermined significance (mgus), waldenstroms macroglobulinemia, or castleman disease.